Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Keila Bariotto-dos-Santos; Danilo Leandro Ribeiro; Rayanne Poletti Guimar&#227;es; Fernando  Eduardo Padovan-Neto

doi:10.3791/62924

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson&#821...

JoVE Journal
Biology

A subscription to JoVE is required to view this content. Sign in or start your free trial.

JoVE Journal Biology

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson’s Disease

Full Text

3,506 Views

06:45 min

October 4, 2021

DOI: 10.3791/62924-v

Keila Bariotto-dos-Santos*¹, Danilo Leandro Ribeiro*¹, Rayanne Poletti Guimarães¹, Fernando Eduardo Padovan-Neto¹

¹Department of Psychology, Faculty of Philosophy, Sciences and Letters of Ribeirão Preto,University of São Paulo

Overview

This study utilizes the 6-hydroxydopamine (6-OHDA) rat model of Parkinson's disease to investigate L-DOPA-induced dyskinesias, aiming to identify therapeutic interventions. The chronic treatment with L-DOPA allows for the assessment of abnormal involuntary movements, providing insights into potential antidyskinetic strategies.

Key Study Components

Research Area

Neuroscience
Pharmacology
Pediatric Medicine

Background

L-DOPA treatment is commonly associated with dyskinesias in Parkinson's disease patients.
Rodent models enable the study of therapeutic effects on dyskinesias.
The 6-OHDA lesion mimics pathophysiological changes seen in human Parkinson's disease.

Methods Used

Stereotaxic administration of 6-OHDA in Sprague-Dawley male rats.
Chronic L-DOPA treatment with benserazide.
Video analysis of abnormal involuntary movements post-treatment.

Main Results

L-DOPA treatment resulted in peak-dose dyskinesias between 30 to 90 minutes.
Patterns of axial, limb, and orolingual movements were systematically scored.
The model effectively mimicked clinical observations of dyskinesias.

Conclusions

This study demonstrates a reliable method to assess L-DOPA-induced dyskinesias.
It underscores the significance of rodent models in developing antidyskinetic therapies.

Frequently Asked Questions

What is L-DOPA-induced dyskinesia?

L-DOPA-induced dyskinesia refers to abnormal involuntary movements that occur as a side effect of long-term treatment with L-DOPA in Parkinson's disease patients.

How is the 6-OHDA model relevant to Parkinson's research?

The 6-OHDA model replicates dopamine depletion seen in Parkinson's disease, allowing for the study of treatments aimed at managing symptoms.

What are the key observations in this study?

Key observations include the timing of dyskinetic movements relative to L-DOPA administration and the assessment of these movements in a controlled environment.

Why is video analysis used in this research?

Video analysis allows for accurate, qualitative scoring of abnormal movements from multiple angles, enhancing the reliability of the observations.

How does this study contribute to antidyskinetic therapy research?

The findings provide insights into the mechanisms and timing of dyskinesias, informing the development of targeted therapeutic interventions.

What implications does this research have for clinical practice?

Understanding dyskinesia onset and severity can guide more effective treatment strategies for Parkinson's patients, improving their quality of life.

Are the animal models used in this study relevant for humans?

Yes, rodent models like the 6-OHDA model have significant predictive validity for human conditions, making them valuable for preclinical research.

Rodent models of L-DOPA-induced dyskinesias are invaluable tools to identify therapeutic interventions to attenuate the development or alleviate the manifestations that emerge due to the repeated administration of L-DOPA. This protocol demonstrates how to induce and analyze dyskinetic-like movements in the unilaterally 6-OHDA-lesioned rat model of Parkinson's disease.

Rating L-DOPA-induced dyskinesias in the 6-hydroxydopamine rat model of the Parkinson's disease is an important preclinical tool to identify effective antidyskinetic interventions. This model is relatively simple, presents low cost, and has similarities to what happens in the clinic. The procedure will be demonstrated by Danilo Leandro Ribeiro, a PhD student in the laboratory.

Begin the experiment with Sprague-Dawley male rats, weighing 200 to 250 grams. House two to three animals per cage under the standard laboratory conditions with food and water available ad libitum. Before the surgery, administer the norepinephrine transporter inhibitor, imipramine, to the rat intraperitoneally.

View the full transcript and gain access to thousands of scientific videos